Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Tata Motors sees modest trading activity, market cap holds strong
Post Content Post Views: 100
Tokyo core CPI growth seen slowing to 2.5% in November: Reuters poll
Post Content Post Views: 104
Gold prices pull back from $2,000 as rate uncertainty persists
Post Content Post Views: 98
Commonwealth Bank bolsters anti-scam defenses with NameCheck
Post Content Post Views: 94
Russia says dual Russian-Italian national arrested for train bombing on behalf of Ukraine
Post Content Post Views: 107
Horizons Mid-Term U.S. Treasury Premium Yield ETF(3) declares CAD 0.15 dividend
Post Content Post Views: 102